SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation on April 27, 2017, reporting events occurring on April 26, 2017. The filing details the entry into a Material Definitive Agreement regarding a private placement of common stock.
Key Financial Metrics and Transaction Details
The filing does not provide historical revenue, profit, cash flow, or margin data. The primary financial event is a capital raise structured as follows:
- Total Offering Size: Up to $25.0 million.
- Purchase Price: $2.60 per share.
- Structure: Three tranches totaling approximately $3.5 million, $16.4 million, and $5.1 million.
- First Tranche: Expected to close April 27, 2017, issuing 1,346,154 shares.
- Second Tranche: Expected within 30 days of the first closing, issuing 6,303,814 shares.
- Third Tranche: Contingent upon stockholder approval following the second tranche.
Material Changes and Governance Implications
Subject to the completion of the second tranche, the agreement mandates governance changes:
- The Board of Directors must increase the number of authorized directors to create two vacant seats.
- These vacancies will be filled by nominees selected by the Purchasers after the 2017 Annual Meeting of Stockholders.
- A Registration Rights Agreement must be executed promptly at the closing of the first tranche.
Outlook, Risks, and Unusual Items
The filing contains forward-looking statements regarding the completion, timing, and size of the offering. Management cautions that actual results may differ materially due to risks and uncertainties described in the Company's 2016 Form 10-K. The securities are being sold under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D to accredited investors for investment purposes only.
Investor Verification Checklist
- Verify the closing of the first tranche on April 27, 2017, and the receipt of proceeds.
- Monitor the timeline for the second tranche closing (within 30 days of the first).
- Confirm the filing of the Registration Rights Agreement as a subsequent 8-K.
- Review the Company's 2016 Form 10-K for detailed risk factors and historical financial performance.
- Track the solicitation of stockholder approval required for the third tranche.